Talus Bio Secures $4.3M in Grants for Cancer Drug Discovery

Date:

Talus Bio, a drug discovery company specializing in cancer treatment, has secured $4.3 million in non-dilutive grant funding for their innovative research. The Seattle-based firm has received two grants totaling $2.3 million from the CARE Fund to support their efforts in developing new transcription factor inhibitors for childhood cancers, specifically rhabdomyosarcoma and neuroblastoma. In addition, Talus Bio was granted a $2 million SBIR fast-track grant from the National Institutes of Health (NIH) to advance their proprietary Multiplexed Assays for the Rational Modulation Of Transcription Factors (MARMOT) platform and accelerate the development of transcription factor drugs.

Talus Bio’s MARMOT platform is a groundbreaking technology that allows for the direct measurement of genome regulatory proteins in live cells, providing unparalleled speed, precision, and resolution in disrupting transcription factors to combat diseases. Transcription factors play a crucial role in controlling gene expression and, when malfunctioning, can drive various diseases including cancer, diabetes, inflammatory diseases, and neurological conditions.

CEO and co-founder of Talus Bio, Alex Federation, expressed his belief that nothing is undruggable and emphasized the potential of transcription factor therapeutics in addressing regulatory protein dysfunction. The substantial funding secured by Talus Bio will enable them to expedite the optimization of new molecules for the treatment of childhood cancers, while also exploring other promising targets for in-house development or collaboration with pharmaceutical partners.

Lindsay Pino, chief technology and co-founder at Talus Bio, highlighted the interdisciplinary nature of their team, combining biochemistry, functional proteomics, and machine learning. This unique approach allows them to measure transcription factors within their native cellular environment, which significantly impacts their folding and function compared to when they are isolated from cells. With the newly obtained funding, Talus Bio can now study the effects of compounds on specific gene activity associated with diseases, as well as any potential interactions with off-target DNA-bound proteins that may lead to side effects during drug development.

See also  European Privacy Watchdog Launches ChatGPT Task Force

Talus Bio’s pipeline also includes the development of the first inhibitor for a previously undruggable transcription factor responsible for driving chordoma, a form of spinal cord cancer that is resistant to chemotherapy.

These recent grants further validate the expertise and potential of Talus Bio in revolutionizing the field of drug discovery and transcription factor therapeutics. Through their cutting-edge technologies and interdisciplinary approach, they aim to bring forth new treatments for cancer, inflammation, and other diseases, ultimately improving patient outcomes and transforming the future of healthcare.

Frequently Asked Questions (FAQs) Related to the Above News

What is Talus Bio?

Talus Bio is a drug discovery company based in Seattle that specializes in cancer treatment. They are focused on developing transcription factor inhibitors and using innovative technologies to combat diseases.

What recent funding has Talus Bio secured?

Talus Bio has secured $4.3 million in non-dilutive grant funding. They received two grants totaling $2.3 million from the CARE Fund to support their research on new transcription factor inhibitors for childhood cancers. They also obtained a $2 million SBIR fast-track grant from the National Institutes of Health (NIH) to advance their proprietary MARMOT platform.

What is the MARMOT platform?

The MARMOT platform is a groundbreaking technology developed by Talus Bio that allows for the direct measurement of genome regulatory proteins in live cells. It provides exceptional speed, precision, and resolution in disrupting transcription factors to combat diseases.

How do transcription factors play a role in diseases like cancer?

Transcription factors are proteins that control gene expression. When they malfunction, they can drive various diseases, including cancer, diabetes, inflammatory diseases, and neurological conditions. Talus Bio aims to develop transcription factor drugs to address regulatory protein dysfunction and treat these diseases.

What can the funding enable Talus Bio to do?

With the substantial funding secured, Talus Bio can expedite the optimization of new molecules for the treatment of childhood cancers. They can also explore other promising targets for in-house development or collaboration with pharmaceutical partners.

What is the interdisciplinary approach employed by Talus Bio?

Talus Bio combines biochemistry, functional proteomics, and machine learning in their research. This interdisciplinary approach allows them to measure transcription factors within their native cellular environment, providing valuable insights for drug development.

What is Talus Bio's pipeline focused on?

In addition to childhood cancers, Talus Bio's pipeline includes the development of the first inhibitor for a previously undruggable transcription factor responsible for driving chordoma, a form of spinal cord cancer that is resistant to chemotherapy.

What is Talus Bio's goal?

Talus Bio aims to revolutionize the field of drug discovery and transcription factor therapeutics. They utilize cutting-edge technologies and an interdisciplinary approach to develop new treatments for cancer, inflammation, and other diseases, with a focus on improving patient outcomes and transforming the future of healthcare.

Please note that the FAQs provided on this page are based on the news article published. While we strive to provide accurate and up-to-date information, it is always recommended to consult relevant authorities or professionals before making any decisions or taking action based on the FAQs or the news article.

Share post:

Subscribe

Popular

More like this
Related

Global Edge Data Centers Market to Reach $46.4 Billion by 2030

Global edge data centers market set to hit $46.4 billion by 2030. Asia-Pacific leads growth with focus on IoT, cloud, and real-time analytics.

Baidu Inc Faces Profit Decline, Boosts Revenue with AI Advertising Sales

Baidu Inc faces profit decline but boosts revenue with AI advertising sales. Find out more about the company's challenges and successes here.

Alexander & Baldwin Holdings Tops FFO Estimates, What’s Next for the REIT?

Alexander & Baldwin Holdings surpasses FFO estimates, investors await future outlook in the REIT industry. Watch for potential growth.

Salesforce Stock Dips Despite New Dividend & Buyback

Despite introducing a new dividend & buyback, Salesforce's stock dipped after strong quarterly results. Investors cautious about future guidance.